Dermatitis News and Research

Latest Dermatitis News and Research

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.

9 Nov 2015

Allergic response can be unexpected clue in medical mystery

Most people think of allergists as the doctors who help solve sneezing, wheezing and itchy eyes. They might not realize allergists are the medical mystery detectives with the expertise to discover what is causing all sorts of unusual allergic responses.

6 Nov 2015

Researchers identify seven genetic risk loci involved in atopic march

There's a typical "career" for some allergic people, and it starts very early on the skin: babies develop atopic dermatitis, food allergies may follow, then comes asthma and later on hay fever. A group of scientists led by Ingo Marenholz and Young-Ae Lee at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, working with colleagues from several institutions, has now identified seven genetic risk loci for this course of disease.

6 Nov 2015

BREVENA Laboratories receives National Eczema Association's Seal of Acceptance award for Restorative Skin Balm

BREVENA Laboratories, LLC, a luxury skincare cosmetics company that combines beauty and advanced medical technology, announces that the National Eczema Association has awarded the Seal of Acceptance to the brand's Restorative Skin Balm.

15 Oct 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

OSU researchers develop new approach to treat eczema

Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.

1 Oct 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

Experts explain how nutrition can influence inflammatory processes and help lower chronic diseases risk

An unresolved inflammatory response is likely to be involved from the early stages of disease development. Controlling inflammation is crucial to human health and a key future preventative and therapeutic target. In a recent ILSI Europe's article published in the British Journal of Nutrition, a coalition of experts explain how nutrition influences inflammatory processes and help reduce chronic diseases risk.

7 Aug 2015

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Women who receive a shorter course of whole breast radiation therapy for early stage disease experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment, researchers report from The University of Texas MD Anderson Cancer Center.

7 Aug 2015

Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510(k) submission for Dermadexin to the U.S. Food & Drug Administration.

4 Aug 2015

Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

Dandruff is a common chronic scalp disorder that is characterised by flaking of the skin of the scalp. As skin cells die, they are shed from the scalp surface. For some people, however, excessive flaking occurs, resulting in dandruff.

28 Jul 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.

25 Jul 2015

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.

24 Jul 2015

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report.

21 Jul 2015

Acupuncture can be more effective in treatment of dermatologic conditions

Medical evidence supports the potential for acupuncture to be significantly more effective in the treatment of dermatologic conditions such as dermatitis, pruritus, and urticaria than alternative treatment options, "placebo acupuncture," or no treatment, according to a review of the medical literature published in the Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

15 Jul 2015

Dermatitis News and Research

Latest Dermatitis News and Research

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Lilly, Merck expand oncology clinical trial collaboration

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

First comprehensive genomic and biologic study of top skin disease-causing microbes

Allergic response can be unexpected clue in medical mystery

Researchers identify seven genetic risk loci involved in atopic march

BREVENA Laboratories receives National Eczema Association's Seal of Acceptance award for Restorative Skin Balm

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

OSU researchers develop new approach to treat eczema

Immune Pharmaceuticals’ CEO establishes stock trading plan

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Experts explain how nutrition can influence inflammatory processes and help lower chronic diseases risk

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Cipher receives Acceptance Review Notification from FDA for 510(k) submission for Dermadexin

Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Acupuncture can be more effective in treatment of dermatologic conditions

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Dermatitis News and Research

Latest Dermatitis News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in